SCHEMBL842166

SCHEMBL842166

CCC(C(=O)OCc1ccccc1)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
EPOR P19235 2/20 0.47
L3MBTL1 Q9Y468 4/20 0.46
LMNA P02545 4/20 0.46
POLB P06746 2/20 0.46
HSD17B10 Q99714 1/20 0.46
MAPK1 P28482 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
KMT2A Q03164 2/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
MAPT P10636 2/20 0.43
HPGD P15428 2/20 0.43
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
RAB9A P51151 2/20 0.42
STAT1 P42224 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ATM Q13315 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL842164 1.00 ALDH1A1 (0.50) ALDH1A1EPORL3MBTL1LMNAPOLB
SCHEMBL18901917 0.89 ALDH1A1 (0.51) ALDH1A1L3MBTL1LMNAMAPK1TDP1
SCHEMBL3632576 0.89 L3MBTL1 (0.54) ALDH1A1EPORL3MBTL1LMNAPOLB
SCHEMBL841610 0.88 EPOR (0.51) ALDH1A1EPORL3MBTL1LMNAPOLB
SCHEMBL841612 0.88 EPOR (0.51) ALDH1A1EPORL3MBTL1LMNAPOLB
SCHEMBL3854880 0.86 EPOR (0.54) ALDH1A1EPORL3MBTL1LMNAPOLB
SCHEMBL7438541 0.86 CTRB1 (0.49) ALDH1A1EPORL3MBTL1LMNAMAPK1
SCHEMBL10315706 0.86 ALDH1A1 (0.47) ALDH1A1EPORL3MBTL1LMNAPOLB
SCHEMBL15448254 0.86 ALDH1A1 (0.47) ALDH1A1EPORL3MBTL1LMNAPOLB
SCHEMBL12799366 0.86 ALDH1A1 (0.47) ALDH1A1EPORL3MBTL1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103946213-A Novel pyrrolidine derivatives as inhibitors of cathepsin HOFFMANN LA ROCHE 2014-07-23 CN disclosed
US-8431733-B2 Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives VIROBAY, INC. (US) 2013-04-30 US disclosed
US-8143448-B2 Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives VIROBAY, INC. (US) 2012-03-27 US disclosed
WO-2009152474-A2 PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES VIROBAY, INC. (US) 2009-12-17 WO disclosed
US-20090312571-A1 PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES VIROBAY, INC. (US) 2009-12-17 US disclosed
WO-2009114633-A1 PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES VIROBAY, INC. (US) 2009-09-17 WO disclosed
US-20090234127-A1 PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES VIROBAY, INC. (US) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234127-A1 PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES CTSS, CTSV, CTSE ALDH1A1 802/4885EPOR 2034/4885L3MBTL1 4621/4885
US-20090312571-A1 PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES HCN3, NPEPPS, HACL2 ALDH1A1 799/4885EPOR 3164/4885L3MBTL1 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.